Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety and tolerability of
 treatment with sofosbuvir (SOF)+ ribavirin (RBV), with or without Pegylated interferon alfa
 (Peg-IFNα-2a/ PEG)) in participants with chronic genotype (GT)-1, 2, 3, and 6 Hepatitis C
 virus (HCV) infection.
Key Inclusion Criteria:

 -  Willing and able to provide written informed consent

 -  HCV RNA ≥ 10^4 IU/mL at screening

 -  HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any
 interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting
 antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with
 medical records that include sufficient detail of prior treatment with IFN to allow
 for categorization of prior response as either IFN Intolerant, non-responder, or
 experiences viral breakthrough or relapse

 -  HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy

 Key Exclusion Criteria:

 -  Current or prior history of any clinically-significant illness (other than HCV)

 -  Pregnant or nursing female or male with pregnant female partner

 -  Chronic liver disease of a non-HCV etiology

 -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

 Note: Other protocol defined Inclusion/Exclusion criteria may apply.